Buy out would need come at $20 plus. She's currently so undervalued. Basic analyst prediction have $14 by end of year with all pending trials. Best part, the hypoxia theory is scientifically being corroborated against the competitor standards which bring in substantial revenue. Great things to come here and great value.
News 
Market Data 
Discover 
